Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation P732L in human DNA topoisomerase IIbeta abolishes DNA cleavage in the presence of calcium and confers drug resistance.

Molecular pharmacology - 1 Jan 2006

Leontiou Chrysoula, Lakey Jeremy H, Lightowlers Robert, Turnbull Rozalind M, Austin Caroline A

Abstract excerpt

The anti cancer drug methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide (mAMSA) targets human DNA topoisomerase IIbeta. We report here the first selection with mAMSA of resistant human topoisomerase IIbeta. Random mutagenesis of human DNA topoisomerase IIbeta cDNA, followed by selection in yeast for resistance to mAMSA, identified betaP732L. This mutant was 10-fold less sensitive to mAMSA and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amsacrine
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Calcium

Share to DNA Topoisomerases, Type II

Share to Drug Resistance, Neoplasm

Share to Magnesium

Share to Plasmids

Share to Surface Plasmon Resonance

Source

Identifiers

PMID: 16239602
DOI: 10.1124/mol.105.015933

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation P732L in human DNA topoisomerase IIbeta abolishes DNA cleavage in the presence of calcium and confers drug resistance.PMID 16239602Read ↗

Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide.Semantic proximity Read ↗

Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks.Semantic proximity Read ↗

A multispecies toolkit of TOP2 hypercleavage mutants for studying topoisomerase II-mediated DNA damage.Semantic proximity Read ↗

A multi-species toolkit of <i>TOP2</i> hypercleavage mutants for studying topoisomerase II–mediated DNA damageSemantic proximity Read ↗

A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons.Semantic proximity Read ↗

Structural and biochemical basis for DNA and RNA catalysis by human Topoisomerase 3βSemantic proximity Read ↗

Mechanistic studies of amsacrine-resistant derivatives of DNA topoisomerase II. Implications in resistance to multiple antitumor drugs targeting the enzyme.Semantic proximity Read ↗

Use of CRISPR/Cas9 with Homology-Directed Repair to Gene-Edit Topoisomerase IIβ in Human Leukemia K562 Cells: Generation of a Resistance Phenotype.Semantic proximity Read ↗

Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.Semantic proximity Read ↗

Mechanisms of camptothecin resistance by human topoisomerase I mutations.Semantic proximity Read ↗

Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha.Semantic proximity Read ↗

CDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.